Treatment Of Osgood Schlatter Syndrome with INDIBA Cell Therapy.
Published:3 March,2022
What follows is the testimony of Caroline Turpin, a physiotherapist using INDIBA technology to treat Osgood Schlatter syndrome.
Testimony
I have been using INDIBA Activ in my practice for four years now, using it to treat a range of conditions, including trauma and rheumatism. However, I have observed particularly good results when treating adolescent patients with Osgood-Schlatter’s or Sever’s syndromes.
Osgood-Schlatter causes significant inflammation and pain in patients. Sadly, as physiotherapists, we are extremely limited in the treatment options for these conditions. Before the addition of INDIBA Activ, patients with this condition had to completely stop any sporting activity to avoid pain.
With INDIBA Activ we can now provide an effective solution to pain and inflammation. Indeed, INDIBA reduces pain from the first session and helps decrease inflammation in the growth cartilage. Moreover, the treatment avoids the use of any medications such as anti-inflammatories.
After 2 or 3 sessions of INDIBA Activ a clear improvement is observed in the patients, with some even resuming partial sporting activity.
However, the complete treatment generally takes 5 to 6 sessions for a complete resumption of sporting activity. Thanks to INDIBA Activ, I can provide a fast and effective solution for patients suffering from Osgood-Schlatter’s and Sever’s syndromes. Indeed, colleagues and doctors in the region even refer patients directly to me for treatment with INDIBA.
There is a large selection of INDIBA devices to use, each of which has its specific uses that correlate to different areas of the body and treatments offered. To explore the INDIBA Activ range, follow this link.
For more news, clinical studies, and articles on INDIBA, please visit our dedicated page here.